Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Adlai Nortye

<< Previous

Bullboard Posts

Next >>

Comment by askretkaon Apr 21, 2021 10:56am

220 Views

Post# 33036819

RE:RE:RE:RE:Adlai Nortye

Might still be relevant. Breast cancer is #1 in new cancers worldwide according to WHO 2020 That kind of surprised me. Numbers of women in China are higher % wise too. ---------- What's behind the huge increase in breast cancer rates in China? Link. https://www.google.com/amp/s/theconversation.com/amp/whats-behind-the-huge-increase-in-breast-cancer-rates-in-china-84224 ---------------------------------- Older article had more recent data but can't find at moment. Out of time fir now. Cheers!

<< Previous

Bullboard Posts

Next >>

Soma Gold poised to extend profitable track record